MOTS-c: The Peptide Your Mitochondria Encode

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA rather than in the nucleus. That is not a marketing detail — mitochondria carry their own small genome, and MOTS-c is one of a handful of peptides known to be encoded there.

It was described in a 2015 Cell Metabolism paper reporting effects on metabolic homeostasis, insulin sensitivity, and diet-induced obesity in mice. The research since has been consistent and almost entirely preclinical.

What makes it unusual

Most signalling peptides are made from nuclear genes, translated in the cytoplasm, and exported. MOTS-c is transcribed from the mitochondrial 12S rRNA region — meaning the mitochondrion produces a signalling molecule that acts on the rest of the cell.

The proposed mechanism centres on AMPK activation, the cellular energy sensor also implicated in the effects of exercise and metformin. That overlap is why MOTS-c is often described as an "exercise mimetic", a phrase that overstates a mechanistic resemblance.

What the research reports

• Metabolic. Improved insulin sensitivity and resistance to diet-induced obesity in mice.

• Exercise. Circulating levels rise with exercise, and studies report improved physical capacity in aged mice.

• Age. Levels decline with age in humans, which is an observation about correlation rather than a demonstrated cause.

• Human trials. No published human dose-ranging or efficacy trial establishes an effective or safe dose.

The vial math

MOTS-c is supplied lyophilised, commonly in 5 mg or 10 mg vials, with figures discussed in milligrams rather than micrograms.

Storage

Storage is the same as any reconstituted vial: 2–8 °C, protected from light, never frozen, and bounded by the shorter of peptide stability and the 28-day limit on bacteriostatic water. The bacteriostatic water guide covers the detail.

The route question nobody resolves

MOTS-c is a signalling molecule that mitochondria release into circulation. Injecting it subcutaneously introduces it from the outside — a different delivery to a different starting point, at concentrations unrelated to the physiological ones.

The rodent studies that produce the headline results generally used intraperitoneal injection at doses derived for mice. Neither the route nor the amount maps cleanly onto a subcutaneous injection in a person, and the surface-area correction that interspecies conversion requires is skipped in most charts. The BPC-157 guide works through why that step matters.

What would change the picture

The MOTS-c literature is more interesting than most in this category — the mitochondrial-encoding finding is genuinely novel biology, published in a serious journal and built on since. What it lacks is the specific thing that would make dosing meaningful:

• A human dose-ranging study, establishing what amount does anything measurable in people.

• Pharmacokinetics, so half-life and clearance inform a schedule rather than guesswork.

• A controlled outcome trial, showing the metabolic effects seen in mice appear in humans.

Until those exist, any chart is an extrapolation dressed as a protocol. That is not an argument that MOTS-c does nothing — it is an argument that nobody currently knows what amount would.

Frequently asked questions

Is MOTS-c an exercise mimetic?

That description comes from a shared mechanism — AMPK activation — not from evidence that it substitutes for exercise. No human trial supports the substitution.

Why do dosing charts vary so much?

Because none derive from a human dose-ranging study. They are extrapolations from rodent work, and different authors extrapolate differently. See the BPC-157 guide for why animal-to-human conversion is not simple multiplication.

Does it need refrigeration?

Once reconstituted, yes, with the usual beyond-use limits.